Renalytix AI plc
https://renalytixai.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Renalytix AI plc
Renalytix’s De Novo Authorization For KidneyIntelX.dkd Paves Way To Other Markets, Channels
Renalytix president Tom Mclain outlined the company’s commercial strategy for its AI-powered blood test to detect early-stage kidney disease in patients with diabetes.
Digital Health Roundup: Digital Therapeutics, Restoring Function, Deals, Investing And Lobbying
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights the push behind digital therapeutics, Abbott’s biowearable line, Exec Chats with iRhythm and Cognetivity, Right To Repair rules for tech, and FDA's guidance on 3D-printing.
Renalytix Collaborates With ADA To Improve Early Detection Of Kidney Disease
The American Diabetes Association and Renalytix will develop a comprehensive interprofessional risk-informed Diabetes Kidney Care Pathway and Model for optimal clinical treatment and risk reduction that can be applied nationally.
MCIT Rule Likely Too Broken For CMS To Implement In December, Analyst Predicts
John Leppard with Washington Analysis says the Medicare agency’s recent delay of the MCIT breakthrough devices rule until mid-December suggests the CMS will likely scrap it altogether and start from scratch.
Company Information
- Industry
- In Vitro Diagnostics
-
Digital Health
- Artificial Intelligence
- Other Names / Subsidiaries
-
- RenalytixAI
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice